Back to clinical trials
RecruitingInterventional
Pilot Study for Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
NCT ID: NCT07630402Sponsor: University of RochesterLast updated: 2026-06-05
Summary
The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).
Arms & interventions
- ProcedureEchocardiogram
12-lead echocardiogram
Outcome measures
Primary
Total Number of imaging tests
Time frame: At the end of therapy, approximately 457 days
Time to completion of HER 2 (human epidermal growth factor receptor 2) target therapy in days
Time frame: end of therapy, approximately 457 days
Eligibility criteria
Sex: FemaleAge: 18 Years to 79 YearsHealthy volunteers: No
Inclusion Criteria:
* Female sex, age 18-79 years.
* Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
* Baseline LVEF ≥ 55 % by 2-D echocardiography.
* Ability to provide informed consent.
Exclusion Criteria:
* Prior HF, myocardial infarction, or cardiomyopathy.
* Atrial fibrillation or significant valvular heart disease.
* Cumulative anthracycline dose ≥ 250 mg/m².
* Pregnancy or lactation.
* Inability to comply with study procedures.
Study locations (1)
Wilmot Cancer Center
Rochester, New York, 14642
Farhan Bajwa, MD, FACC · Principal Investigator